Affibody named Ulf Boberg as its new chief executive officer this week. The appointment is effective June 1.
He replaces Carl-Johan Dalsgaard, who has been acting CEO since December 2005. Dalsgaard is a partner of Affibody's largest shareholder, HealthCap, and will remain a non-executive Affibody director.
Boberg came to Affibody in January 2006 as senior vice-president for development. Prior to that, he was CEO of Global Genomics AB. He also held the senior roles of vice president and head of the development division at Astra Pain Control, vice president and R&D site general manager at AstraZeneca, head of medical research at Gambro, CEO of PMC Clinical Research AB, and CEO of Alfta Rehab Center.
Daniel Caserza, interim chief financial officer of Ciphergen Biosystems, is expected to resign today, according to documents filed with the Securities and Exchange Commission early this week. He became the interim CFO in March after Matthew Hogan abruptly resigned.
Gail Page, the company's president and chief executive officer, will act as interim chief financial officer until the company finds a permanent replacement.
Ciphergen has hired the Financial Leadership Group to help it prepare financial statements until a replacement is appointed.
Illumina appointed Christian Cabou as senior vice president and general counsel, the company said this week.
Prior to becoming Alnylam's CEO, Maraganore was senior vice-president of strategic product development for Millennium Pharmaceuticals, vice president of strategic planning and M&A, and general manager of Millennium BioTherapeutics, a former subsidiary of Millennium.
Maraganore is a director of the Biotechnology Industry Organization.
Hakon Hakonarson is leaving Decode Genetics to pursue other interests, the company said earlier this week.
Hakonarson has been with Decode for eight years and held various positions, most recently as vice president of business development.
Tomas Sigurdsson, Decode's vice president of treasury and new alliances, will assume responsibility for the company's business development